Market revenue in 2023 | USD 637.3 million |
Market revenue in 2030 | USD 964.9 million |
Growth rate | 6.1% (CAGR from 2023 to 2030) |
Largest segment | Crohn's disease |
Fastest growing segment | Ulcerative Colitis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Crohn's Disease, Ulcerative Colitis |
Key market players worldwide | AbbVie Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Biogen Inc, Novartis AG ADR, Eli Lilly and Co, UCB SA, Merck & Co Inc, Johnson & Johnson, Celltrion Healthcare |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to inflammatory bowel disease treatment market will help companies and investors design strategic landscapes.
Crohn's disease was the largest segment with a revenue share of 55.64% in 2023. Horizon Databook has segmented the China inflammatory bowel disease treatment market based on crohn's disease, ulcerative colitis covering the revenue growth of each sub-segment from 2018 to 2030.
The launch of products is a major strategy used by players in the region. For instance, in July 2021, Tillotts Pharma AG announced the launch of Asacol (800 mg tablets) in China for treatment of moderate to mild ulcerative colitis.
In March 2020, Entyvio by Takeda received approval in China for the treatment of severe to moderate ulcerative colitis patients that are not cured using first-line therapies. The use of biologics is limited in the country, limiting the scope of growth.
Treatment options in the country are antibiotics, immunomodulators, corticosteroids, and aminosalicylates. Increasing involvement of local Chinese players in the development of biosimilars for biological products is expected to drive market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the China inflammatory bowel disease treatment market , including forecasts for subscribers. This country databook contains high-level insights into China inflammatory bowel disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account